Please login to the form below

Not currently logged in
Email:
Password:

Kevin Sin joins GSK

He becomes senior VP, head of worldwide business development

Kevin SinKevin Sin has joined GlaxoSmithKline as its senior vice president, head of worldwide business development for pharmaceutical research and development.

In this position, Sin will play a role in strengthening GSK’s pharmaceutical pipeline and identifying enabling technologies to enhance delivery of new medicines for patients.

He said: “The incredible pace of scientific and technical innovation that is happening around the world is significant and presents an abundance of opportunities to combine GSK’s strengths and capabilities with that of others to pursue big ideas in science and medicine.

“I look forward to working with the team to explore collaborations that can accelerate the discovery and development of new medicines with the potential to significantly improve human health.”

Sin joins GSK from Genetech, where he served as vice president and global head of oncology business development and has worked within the pharmaceutical and life science industry for over 20 years.

Dr Hal Barron, chief scientific officer and president of research and development, GSK, said: “I am extremely excited to have Kevin join GSK. Gaining access to the best science and technologies across the world as well as establishing highly productive collaborations with academia and industry, play an important role in creating a world-class R&D organization.

“Kevin’s leadership skills, significant expertise and successful track record make him the ideal person to lead Business Development activities for R&D.”

Sin will report to Hal Barron and will be based at the group’s San Francisco office.

1st June 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics